Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Protandim Amyotrophic Lateral Sclerosis	Duke University	P2	B (57)
prt3789 Non-Small Cell Lung Carcinoma	Prelude Therapeutics	P2	B (57)
Pyridostigmine Parkinson Disease	University of Vermont Medical Center	P2	B (57)
Pyy(3-36) Obesity Disorder	University College, London	P2	B (57)
Raltitrexed Rectal Carcinoma	Fudan University	P2	B (57)
Ranolazine Amyotrophic Lateral Sclerosis	Swathy Chandrashekhar, MBBS	P2	B (57)
Regorafenib Metastatic Malignant Neoplasm In The Brain	Neonc Technologies, Inc.	P2	B (57)
Regorafenib Digestive System Neuroendocrine Neoplasm	Translational Research in Oncology	P2	B (57)
Regorafenib Neoplasm	Helsinki University Central Hospital	P2	B (57)
Regorafenib Non-Small Cell Lung Carcinoma	Neonc Technologies, Inc.	P2	B (57)
Regorafenib Urothelial Carcinoma	Neonc Technologies, Inc.	P2	B (57)
Relatlimab Mucosal Melanoma	University Health Network, Toronto	P2	B (57)
Rencofilstat Fibrotic Liver Disease	Hepion Pharmaceuticals, Inc.	P2	B (57)
Rencofilstat Metabolic Dysfunction-Associated Steatotic Liver Disease	Hepion Pharmaceuticals, Inc.	P2	B (57)
Resiquimod Melanoma	Institut Bergonié	P2	B (57)
Resminostat Sezary Syndrome	4SC AG	P2	B (57)
Retinol Vitamin A Deficiency	West China Hospital	P2	B (57)
Rifaximin Sickle Cell Disease	Bausch Health Americas, Inc.	P2	B (57)
Rimegepant Irritable Bowel Syndrome	Mayo Clinic	P2	B (57)
Risperidone Inflammatory Disease	Hasanuddin University	P2	B (57)
Rituximab Therapy-Related Myeloid Neoplasm	M.D. Anderson Cancer Center	P2	B (57)
Rituximab Classic Hodgkin Lymphoma	Yale University	P2	B (57)
Rituximab Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	B (57)
Rivoceranib Colorectal Cancer	Yunpeng Liu	P2	B (57)
Roflumilast Metabolic Dysfunction-Associated Steatohepatitis	Tanta University	P2	B (57)

Showing 3401 to 3425 of 13,145 assets

PreviousPage 137 of 526Next